In silico evaluation of the inhibitory effect of antiretrovirals Atazanavir and Darunavir on the main protease of SARS-CoV-2: docking studies and molecular dynamics

Detalhes bibliográficos
Autor(a) principal: Silva, José Danilo de Sousa
Data de Publicação: 2020
Outros Autores: Leite, Samuel da Costa, Silva, Maria Thalita Sobral da, Meirelles, Lyghia Maria Araújo, Andrade, Anderson Wilbur Lopes
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/6562
Resumo: SARS-CoV-2 is part of an RNA virus family described again in 2019, causing the Covid-19 disease. The integration of computational strategies is of great importance in the identification and development of promising new compounds. Atazanavir and Darunavir, were designed to combat resistance to mutant drugs mainly by increasing the number of polar interactions with the main atoms in the HIV protease chain. This study aims to assess the molecular interaction of the drugs Atazanavir and Darunavir with the main SARS-CoV-2 protease through docking and molecular dynamics studies. This is a descriptive, experimental study with a qualitative and quantitative approach on the subject. For that, using the programs BIOVIA Discovery Studio, PyMol, AutoDock Tools 1.5.6, AutoDock Vina, the modeling and simulation of the anchoring of the drug at the action site were carried out. Lower scores were demonstrated, with -7.0 (Darunavir) the closest to the UAW 247 Inhibitor. It is possible to notice that the drugs showed similar residual bonds, also, in relation to the protease structure, the closest tested molecule was Atazanavir. Taking into account the stability of the RMSD values, it is valid to infer that in relation to the UAW 247 inhibitor, the drug Atazanavir is the one that best resembles, unlike Darunavir, which presents greater variations. The two drugs fit into the binding site mainly due to electrostatic interactions and hydrogen bonds. Atazanavir is the most similar to molecular activity, and Darunavir is the one with the best anchoring score.
id UNIFEI_9441a261300717af22c4c2f02c31af11
oai_identifier_str oai:ojs.pkp.sfu.ca:article/6562
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling In silico evaluation of the inhibitory effect of antiretrovirals Atazanavir and Darunavir on the main protease of SARS-CoV-2: docking studies and molecular dynamicsEvaluación in silico del efecto inhibitorio de los antirretrovirales Atazanavir y Darunavir sobre la proteasa principal del SARS-CoV-2: estudios de acoplamiento y dinámica molecularAvaliação in silico do efeito inibitório dos antirretrovirais Atazanavir e Darunavir sobre a principal protease do SARS-CoV-2: estudos de docking e dinâmica molecularMolecular anchorageProtease inhibitorUse of medicines.Ancoragem molecularInibidor da proteaseUso de medicamentos.Anclaje molecularInhibidor de proteaseUso de medicinas.SARS-CoV-2 is part of an RNA virus family described again in 2019, causing the Covid-19 disease. The integration of computational strategies is of great importance in the identification and development of promising new compounds. Atazanavir and Darunavir, were designed to combat resistance to mutant drugs mainly by increasing the number of polar interactions with the main atoms in the HIV protease chain. This study aims to assess the molecular interaction of the drugs Atazanavir and Darunavir with the main SARS-CoV-2 protease through docking and molecular dynamics studies. This is a descriptive, experimental study with a qualitative and quantitative approach on the subject. For that, using the programs BIOVIA Discovery Studio, PyMol, AutoDock Tools 1.5.6, AutoDock Vina, the modeling and simulation of the anchoring of the drug at the action site were carried out. Lower scores were demonstrated, with -7.0 (Darunavir) the closest to the UAW 247 Inhibitor. It is possible to notice that the drugs showed similar residual bonds, also, in relation to the protease structure, the closest tested molecule was Atazanavir. Taking into account the stability of the RMSD values, it is valid to infer that in relation to the UAW 247 inhibitor, the drug Atazanavir is the one that best resembles, unlike Darunavir, which presents greater variations. The two drugs fit into the binding site mainly due to electrostatic interactions and hydrogen bonds. Atazanavir is the most similar to molecular activity, and Darunavir is the one with the best anchoring score.El SARS-CoV-2 es parte de una familia de virus de ARN descrita nuevamente en 2019, que causa la enfermedad de Covid-19. La integración de estrategias computacionales es de gran importancia en la identificación y desarrollo de nuevos compuestos prometedores. Atazanavir y Darunavir, fueron diseñados para combatir la resistencia a las drogas mutantes principalmente aumentar el número de interacciones polares con átomos principales en cadena de la proteasa del VIH. Este estudio tiene como objetivo evaluar la interacción molecular de los medicamentos Atazanavir y Darunavir con la proteasa principal del SARS-CoV-2 através de estudios de acoplamiento y dinámica molecular. Este es un estudio descriptivo, experimental con un enfoque cuali-cuantitativo sobre el tema. Para ello, utilizando los programas BIOVIA Discovery Studio, PyMol, AutoDock Tools 1.5.6, AutoDock Vina, se realizó el modelado y simulación del anclaje del fármaco en sitio de acción. Se demostraron puntuaciones más bajas, siendo -7.0 (Darunavir) más cercano al inhibidor UAW 247. Es posible notar que los fármacos mostraron conexiones residuales similares, también, en relación con estructura de la proteasa, la molécula probada más cercana fue Atazanavir. Teniendo en cuenta la estabilidad de los valores de RMSD, es válido inferir que, en relación con el inhibidor de UAW 247, el medicamento Atazanavir es el que mejor se asemeja, el Darunavir, presenta mayores variaciones. Las dos drogas encajan en el sitio de unión principalmente debido a interacciones electrostáticas y enlaces de hidrógeno. Atazanavir es más similar a la actividad molecular, y Darunavir es el que tiene mejor puntuación de anclaje.O SARS-CoV-2 faz parte de uma família vírus de RNA novamente descrito em 2019, sendo o causador da doença Covid-19. A integração de estratégias computacionais tem grande importância na identificação e desenvolvimento de novos compostos promissores. Atazanavir e Darunavir, foram projetados para combater a resistência a fármacos mutantes principalmente por meio do aumento do número de interações polares com os principais átomos da cadeia da protease do HIV. Este estudo visa avaliar a interação molecular dos fármacos Atazanavir e Darunavir com a principal protease do SARS-CoV-2 através de estudos de docking e dinâmica molecular. Trata-se de um estudo descritivo, do tipo experimental com uma abordagem quali-quantitativa sobre o tema. Para tanto utilizando-se dos programas BIOVIA Discovery Studio, PyMol, AutoDock Tools 1.5.6, AutoDock Vina, foram realizadas a modelagem e simulação de ancoragem do fármaco no local de ação. Foram demonstradas pontuações menores, sendo -7.0 (Darunavir) a mais próxima do Inibidor UAW 247. É possível perceber que os fármacos demonstraram ligações residuais semelhantes, também, em relação à estrutura da protease, a molécula testada mais próxima foi o Atazanavir. Levando em consideração a estabilidade dos valores RMSD, é válido inferir que em relação ao inibidor UAW 247, o fármaco Atazanavir é aquele que melhor se assemelha, ao contrário do Darunavir, que apresenta variações maiores. Os dois fármacos encaixaram no local de ligação devido principalmente, a interações eletrostáticas e pontes de hidrogênio. O Atazanavir é o que mais se assemelha à atividade molecular, e o Darunavir é o que apresenta melhor pontuação de ancoragem.Research, Society and Development2020-07-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/656210.33448/rsd-v9i8.6562Research, Society and Development; Vol. 9 No. 8; e826986562Research, Society and Development; Vol. 9 Núm. 8; e826986562Research, Society and Development; v. 9 n. 8; e8269865622525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/6562/5899Copyright (c) 2020 José Danilo de Sousa Silva, Samuel da Costa Leite, Maria Thalita Sobral da Silvahttp://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSilva, José Danilo de SousaLeite, Samuel da CostaSilva, Maria Thalita Sobral daMeirelles, Lyghia Maria AraújoAndrade, Anderson Wilbur Lopes2020-08-20T18:00:17Zoai:ojs.pkp.sfu.ca:article/6562Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:29:39.115523Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv In silico evaluation of the inhibitory effect of antiretrovirals Atazanavir and Darunavir on the main protease of SARS-CoV-2: docking studies and molecular dynamics
Evaluación in silico del efecto inhibitorio de los antirretrovirales Atazanavir y Darunavir sobre la proteasa principal del SARS-CoV-2: estudios de acoplamiento y dinámica molecular
Avaliação in silico do efeito inibitório dos antirretrovirais Atazanavir e Darunavir sobre a principal protease do SARS-CoV-2: estudos de docking e dinâmica molecular
title In silico evaluation of the inhibitory effect of antiretrovirals Atazanavir and Darunavir on the main protease of SARS-CoV-2: docking studies and molecular dynamics
spellingShingle In silico evaluation of the inhibitory effect of antiretrovirals Atazanavir and Darunavir on the main protease of SARS-CoV-2: docking studies and molecular dynamics
Silva, José Danilo de Sousa
Molecular anchorage
Protease inhibitor
Use of medicines.
Ancoragem molecular
Inibidor da protease
Uso de medicamentos.
Anclaje molecular
Inhibidor de protease
Uso de medicinas.
title_short In silico evaluation of the inhibitory effect of antiretrovirals Atazanavir and Darunavir on the main protease of SARS-CoV-2: docking studies and molecular dynamics
title_full In silico evaluation of the inhibitory effect of antiretrovirals Atazanavir and Darunavir on the main protease of SARS-CoV-2: docking studies and molecular dynamics
title_fullStr In silico evaluation of the inhibitory effect of antiretrovirals Atazanavir and Darunavir on the main protease of SARS-CoV-2: docking studies and molecular dynamics
title_full_unstemmed In silico evaluation of the inhibitory effect of antiretrovirals Atazanavir and Darunavir on the main protease of SARS-CoV-2: docking studies and molecular dynamics
title_sort In silico evaluation of the inhibitory effect of antiretrovirals Atazanavir and Darunavir on the main protease of SARS-CoV-2: docking studies and molecular dynamics
author Silva, José Danilo de Sousa
author_facet Silva, José Danilo de Sousa
Leite, Samuel da Costa
Silva, Maria Thalita Sobral da
Meirelles, Lyghia Maria Araújo
Andrade, Anderson Wilbur Lopes
author_role author
author2 Leite, Samuel da Costa
Silva, Maria Thalita Sobral da
Meirelles, Lyghia Maria Araújo
Andrade, Anderson Wilbur Lopes
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Silva, José Danilo de Sousa
Leite, Samuel da Costa
Silva, Maria Thalita Sobral da
Meirelles, Lyghia Maria Araújo
Andrade, Anderson Wilbur Lopes
dc.subject.por.fl_str_mv Molecular anchorage
Protease inhibitor
Use of medicines.
Ancoragem molecular
Inibidor da protease
Uso de medicamentos.
Anclaje molecular
Inhibidor de protease
Uso de medicinas.
topic Molecular anchorage
Protease inhibitor
Use of medicines.
Ancoragem molecular
Inibidor da protease
Uso de medicamentos.
Anclaje molecular
Inhibidor de protease
Uso de medicinas.
description SARS-CoV-2 is part of an RNA virus family described again in 2019, causing the Covid-19 disease. The integration of computational strategies is of great importance in the identification and development of promising new compounds. Atazanavir and Darunavir, were designed to combat resistance to mutant drugs mainly by increasing the number of polar interactions with the main atoms in the HIV protease chain. This study aims to assess the molecular interaction of the drugs Atazanavir and Darunavir with the main SARS-CoV-2 protease through docking and molecular dynamics studies. This is a descriptive, experimental study with a qualitative and quantitative approach on the subject. For that, using the programs BIOVIA Discovery Studio, PyMol, AutoDock Tools 1.5.6, AutoDock Vina, the modeling and simulation of the anchoring of the drug at the action site were carried out. Lower scores were demonstrated, with -7.0 (Darunavir) the closest to the UAW 247 Inhibitor. It is possible to notice that the drugs showed similar residual bonds, also, in relation to the protease structure, the closest tested molecule was Atazanavir. Taking into account the stability of the RMSD values, it is valid to infer that in relation to the UAW 247 inhibitor, the drug Atazanavir is the one that best resembles, unlike Darunavir, which presents greater variations. The two drugs fit into the binding site mainly due to electrostatic interactions and hydrogen bonds. Atazanavir is the most similar to molecular activity, and Darunavir is the one with the best anchoring score.
publishDate 2020
dc.date.none.fl_str_mv 2020-07-30
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/6562
10.33448/rsd-v9i8.6562
url https://rsdjournal.org/index.php/rsd/article/view/6562
identifier_str_mv 10.33448/rsd-v9i8.6562
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/6562/5899
dc.rights.driver.fl_str_mv Copyright (c) 2020 José Danilo de Sousa Silva, Samuel da Costa Leite, Maria Thalita Sobral da Silva
http://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 José Danilo de Sousa Silva, Samuel da Costa Leite, Maria Thalita Sobral da Silva
http://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 9 No. 8; e826986562
Research, Society and Development; Vol. 9 Núm. 8; e826986562
Research, Society and Development; v. 9 n. 8; e826986562
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052655220031488